Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 20th Euro-Global Summit on Cancer Therapy
&
Radiation Oncology Brussels, Belgium.

Day 1 :

OMICS International Euro Cancer 2017 International Conference Keynote Speaker Wassil Nowicky photo
Biography:

Wassil Nowicky received degree of Dr. Sci. Tech at the University of Vienna. He is the Director of Nowicky Farma and the Inventor of the Anticancer Preparation NSC631570. He is a Real Member of the New York Academy of Sciences, Member of the European Union for Applied Immunology and of the American Association for Scientific Progress, Honorary Doctor of the Janka Kupala University in Hrodno, Doctor “honoris causa” of the Open International University on Complex Medicine in Colombo, and Honorary Member of the Austrian Albert Schweitzer Society. He has published more than 49 papers in reputed journals.

Abstract:

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. There is an assumption that the same high selective cytotoxicity of drug on tumor cells of different origin is the result of its interaction with an ubiquitous tumor-specific (or overexpressed in tumor cells) compound involved in the induction of cell death. However, this compound remains to be found.

OMICS International Euro Cancer 2017 International Conference Keynote Speaker Jan Jacques Michiels photo
Biography:

Jan Jacques Michiels is a Multidisciplinary Internist in Blood Coagulation & Vascular Medicine Center, Erasmus Tower, NL. He is the Professor of Nature Medicine & Health, Clinical and Molecular Genetics, Blood & Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant of Blood Coagulation & Vascular Medicine. He is also an Academic Consultant of Pharmaceutical and Industrial Medicine. He is Editor of Journal of Hematology & Thromboembolic Diseases and World Journal of Hematology, and Editor in Chief of World Journal of Clinical Cases.

Abstract:

The broad spectrum of JAK2 V617F mutated trilinear phenotypes varies from essential thrombocythemia (ET), prodromal polycythemia vera (PV), masked PV, erythrocythemic PV, classical PV, and PV complicated by splenomegaly and myelofibrosis (MF). ET heterozygous for the JAK2 V617F mutation is associated with normal life expectancy. JAK2 mutation load increases from less than 50% in early stage PV to 100% in overt and advanced PV and MF. Pretreatment bone marrow morphology and cellularity distinguish JAK2 V617F mutated trilinear MPN from calreticulin (CALR) and MPL mutated MPN. The morphology of clustered large pleomorphic megakaryocytes with hyperlobulated nuclei are similar in JAK2 V67F ET and PV patients. CALR mutated thrombocythemia shows characteristic bone marrow features of primary dual megakaryocytic granulocytic myeloproliferation (PMGM) without features of PV. MPL515 mutated thrombocythemia is featured by monolinear proliferation of large to giant megakaryocytes with hyperlobulated staghorn like nuclei. JAK2, CALR and MPL allele burden slowly increases together with the degree of splenomegaly, myelofibrosis and constitutional symptoms during life long follow-up. The presence of epigenetic mutations at increasing age predicts unfavorable outcome in JAK2, CALR and MPL mutated MPN. Low dose aspirin in ET and phlebotomy on top of aspirin in PV is mandatory to prevent platelet-mediated microvascular circulation disturbances. Pegaylated interferon is the first line myeloreductive treatment option in prodromal and early stage JAK2 mutated PV and in CALR and MPL mutated thrombocythemia to postpone the use of hydrozyurea as long as possible.

OMICS International Euro Cancer 2017 International Conference Keynote Speaker Jerome Check photo
Biography:

Jerome H Check is a Professor of Obstetrics and Gynecology and Division Head of Reproductive Endocrinology at Cooper Medical School of Rowan University, New Jersey, USA. He is also board certified in Internal Medicine and Medical Endocrinology. He is a lead author (predominantly) or co-author of over 750 peer-reviewed manuscripts. His first publication in a Cancer Journal was in 1971 and he has several recent publications involving his research into Cancer Immunology, especially as it relates to similarities of the fetal placental unit and cancer in avoiding immune surveillance.

Abstract:

The progesterone receptor modulator mifepristone has been found to prolong length and quality of life in mice and humans with advanced cancers of various types. Most of these cancers are not known to be associated with the classic nuclear progesterone (P) receptor. Some of these tumors in controlled animal studies include leukemia, lung and testicular cancer, and prostate cancer (the latter associated with nuclear P receptor in humans, not sure in mice). Human cancers that benefited from mifepristone therapy without evidence of presence of classic nuclear receptor includes colon, pancreatic, renal cell, transitional cell carcinoma of the renal pelvis, thymic epithelial cell, malignant fibrous histiocytoma, and small and nonsmall cell lung cancer. Anecdotal benefits have been found also in those with the presence of the classic nuclear P receptor, e.g., breast and ovarian cancer and leiomyosarcoma, but the benefits may be from non-epigenetic effects on membrane P receptors. The mechanism is believed to be by inhibiting the conversion of a 90 kDa 757 amino acid “parent” protein, known as the progesterone induced blocking factor (PIBF), to intracytoplasmic splice variants which act to suppress natural killer cell activity by stabilizing perforin granules. PIBF also causes a shift from TH1 cytotoxic T-cells to antibody secreting TH2 cytokine dominant T-cells. Some of the anecdotal cases have improved quality and length of life despite the severity of the cancer leaving little question of its efficacy in these cases, especially since the mifepristone was used as single agent therapy.

Keynote Forum

Junliang Liu

University of Manitoba, Canada

Keynote: Explore the ways to manage brain metastases for better outcome

Time : 11:35-12:10

OMICS International Euro Cancer 2017 International Conference Keynote Speaker Junliang Liu photo
Biography:

Junliang Liu underwent his Radiation Oncology Residency in University of Manitoba, Canada from 2000 to 2005. Since July 2005, he has been an attending Radiation Oncologist working at CancerCare Manitoba, Canada. He was the Radiation Oncology Residency Program Director from 2006 to 2012. He graduated from West China University of Medical Sciences (now is the Medical School Sichuan University), China in 1983 and pursued a Master’s Degree in Pediatrics from 1983 to 1986 in the same medical school. He was a Pediatrician working at Sichuan Provincial People’s Hospital, China from 1986 to 1991. He was a Guest Researcher supervised by Professor Hans Wigzell at the Department of Immunology, Karolinska Institute, Sweden, from 1991 to 1994. He earned a PhD in Immunology from La Trobe University, Melbourne, Australia in 1997, and conducted Post-Doctoral Research in Immunology at University of Alberta, Canada, from 1997 to 2000, before his residency training in Radiation Oncology. His publications included the ones in the prestigious journals of Nature Medicine and Proceedings of the National Academy of Sciences of the United States of America (PNAS). His current research interest is the treatment outcomes of gastrointestinal malignancies, breast cancer, and metastatic cancer.

Abstract: